103 related articles for article (PubMed ID: 26495982)
1. T-Cell Surface Antigens and sCD30 as Biomarkers of the Risk of Rejection in Solid Organ Transplantation.
Wieland E; Shipkova M
Ther Drug Monit; 2016 Apr; 38 Suppl 1():S29-35. PubMed ID: 26495982
[TBL] [Abstract][Full Text] [Related]
2. Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs?
Schlaf G; Altermann WW; Rothhoff A; Seliger B
Histol Histopathol; 2007 Nov; 22(11):1269-79. PubMed ID: 17647199
[TBL] [Abstract][Full Text] [Related]
3. Soluble CD30 and HLA antibodies as potential risk factors for kidney transplant rejection.
Slavcev A; Lácha J; Honsová E; Sajdlová H; Lodererová A; Vitko S; Skibová J; Striz I
Transpl Immunol; 2005 Jun; 14(2):117-21. PubMed ID: 15935302
[TBL] [Abstract][Full Text] [Related]
4. Soluble CD30 does not predict late acute rejection or safe tapering of immunosuppression in renal transplantation.
Valke LL; van Cranenbroek B; Hilbrands LB; Joosten I
Transpl Immunol; 2015 Jan; 32(1):18-22. PubMed ID: 25446808
[TBL] [Abstract][Full Text] [Related]
5. Value of soluble CD30 in liver transplantation.
Fábrega E; Unzueta MG; Cobo M; Casafont F; Amado JA; Romero FP
Transplant Proc; 2007 Sep; 39(7):2295-6. PubMed ID: 17889168
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of pre transplant T-cell activation status by soluble CD 30 determination.
Abbas K; Muzaffar R; Zafar MN; Mubarak M; Naqvi SA; Rizvi SA
J Pak Med Assoc; 2009 Apr; 59(4):212-5. PubMed ID: 19402280
[TBL] [Abstract][Full Text] [Related]
7. Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy.
Grenzi PC; Campos ÉF; Tedesco-Silva H; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-Delima M
Transpl Immunol; 2013 Dec; 29(1-4):34-8. PubMed ID: 23928467
[TBL] [Abstract][Full Text] [Related]
8. Clinical relevance of pre and post-transplant immune markers in kidney allograft recipients: anti-HLA and MICA antibodies and serum levels of sCD30 and sMICA.
Solgi G; Furst D; Mytilineos J; Pourmand G; Amirzargar AA
Transpl Immunol; 2012 Mar; 26(2-3):81-7. PubMed ID: 22182633
[TBL] [Abstract][Full Text] [Related]
9. Post-transplant soluble CD30 levels are associated with early subclinical rejection in kidney transplantation.
Grenzi PC; Campos ÉF; Silva HT; Felipe CR; Franco MF; Soares MF; Medina-Pestana JO; Gerbase-DeLima M
Transpl Immunol; 2015 Mar; 32(2):61-5. PubMed ID: 25698648
[TBL] [Abstract][Full Text] [Related]
10. Lymphocyte surface molecules as immune activation biomarkers.
Wieland E; Shipkova M
Clin Biochem; 2016 Mar; 49(4-5):347-54. PubMed ID: 26247177
[TBL] [Abstract][Full Text] [Related]
11. Does pretransplant soluble CD30 serum concentration affect deceased-donor kidney graft function 3 years after transplantation?
Kovac J; Arnol M; Vidan-Jeras B; Bren AF; Kandus A
Transplant Proc; 2008 Jun; 40(5):1357-61. PubMed ID: 18589105
[TBL] [Abstract][Full Text] [Related]
12. Activated effector and memory T cells contribute to circulating sCD30: potential marker for islet allograft rejection.
Saini D; Ramachandran S; Nataraju A; Benshoff N; Liu W; Desai N; Chapman W; Mohanakumar T
Am J Transplant; 2008 Sep; 8(9):1798-808. PubMed ID: 18786226
[TBL] [Abstract][Full Text] [Related]
13. Soluble CD30 and Hepatocyte growth factor as predictive markers of antibody-mediated rejection of the kidney allograft.
Pavlova Y; Viklicky O; Slatinska J; Bürgelova M; Süsal C; Skibova J; Honsová E; Striz I; Kolesar L; Slavcev A
Transpl Immunol; 2011 Jul; 25(1):72-6. PubMed ID: 21376809
[TBL] [Abstract][Full Text] [Related]
14. Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2.
Velásquez SY; García LF; Opelz G; Alvarez CM; Süsal C
Transplantation; 2013 Jul; 96(2):154-61. PubMed ID: 23857000
[TBL] [Abstract][Full Text] [Related]
15. Pre-transplant soluble CD30 level as a predictor of not only acute rejection and graft loss but pneumonia in renal transplant recipients.
Wang D; Wu WZ; Chen JH; Yang SL; Wang QH; Zeng ZX; Tan JM
Transpl Immunol; 2010 Feb; 22(3-4):115-20. PubMed ID: 20036333
[TBL] [Abstract][Full Text] [Related]
16. High serum soluble CD30 does not predict acute rejection in liver transplant patients.
Matinlauri I; Höckerstedt K; Isoniemi H
Transplant Proc; 2006 Dec; 38(10):3601-4. PubMed ID: 17175343
[TBL] [Abstract][Full Text] [Related]
17. Soluble CD30 and ELISA-detected human leukocyte antigen antibodies for the prediction of acute rejection in pediatric renal transplant recipients.
Billing H; Sander A; Süsal C; Ovens J; Feneberg R; Höcker B; Vondrak K; Grenda R; Friman S; Milford DV; Lucan M; Opelz G; Tönshoff B
Transpl Int; 2013 Mar; 26(3):331-8. PubMed ID: 23279372
[TBL] [Abstract][Full Text] [Related]
18. Relative reductions in soluble CD30 levels post-transplant predict acute graft function in islet allograft recipients receiving three different immunosuppression protocols.
Hire K; Hering B; Bansal-Pakala P
Transpl Immunol; 2010 Aug; 23(4):209-14. PubMed ID: 20600901
[TBL] [Abstract][Full Text] [Related]
19. Soluble CD30 levels in recipients undergoing heart transplantation do not predict post-transplant outcome.
Ypsilantis E; Key T; Bradley JA; Morgan CH; Tsui S; Parameshwar J; Taylor CJ
J Heart Lung Transplant; 2009 Nov; 28(11):1206-10. PubMed ID: 19782609
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of soluble CD30 as an immunologic marker in heart transplant recipients.
Spiridon C; Hunt J; Mack M; Rosenthal J; Anderson A; Eichhorn E; Magee M; Dewey T; Currier M; Nikaein A
Transplant Proc; 2006 Dec; 38(10):3689-91. PubMed ID: 17175368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
